Publication
La Cour suprême du Canada tranche : les cadres ne pourront se syndiquer au Québec
Le 19 avril dernier, la Cour suprême du Canada a rendu une décision fort attendue en matière de syndicalisation des cadres.
Mondial | Publication | November 2016
The European Medicines Agency (EMA) issued guidance on the implementation of its Policy 0070 on the publication of clinical data for medicines, including with respect to anonymization of clinical reports for publication. As background, please see our previous briefing on the EMA’s new approach to transparency of clinical studies here. As of October 2016, all drug manufacturers that are making a marketing authorization application under the centralized procedure in Europe will be subject to the new guidance.1
Similar to the US Food & Drug Administration, the EMA ensures that medicines sold in the EU markets under a centralized marketing authorization are safe and effective. EMA Policy 0070 provides for the proactive publication by the EMA of clinical data from clinical reports submitted to it. The clinical reports will be made available to the public for general information, academic use and other non-commercial purposes. One of the underlying concerns in this shift toward transparency is the privacy of clinical study subjects.
Balancing subject privacy and transparency presents drug manufacturers with a difficult task—how to increase transparency of clinical studies while also attenuating the risk of subject reidentification. In its guidance, the EMA discusses three approaches to anonymization of clinical reports:
These anonymization techniques can be used separately or in combination. One industry commenter suggests that manufacturers should focus on anonymizing patient-level data to ensure that downstream uses of that data are secure, including use in clinical reports, and maintains that this method is superior to ad hoc masking of the data, which may be more prone to error. However, the EMA’s guidance does not mandate use of any specific methodology.
Whilst the first phase of implementing EMA Policy 0070 has been focused on publication of clinical data which relates to clinical reports only, the second phase will involve the EMA finding the most appropriate way to make available individual patient data in compliance with privacy and data protection laws. Pharmaceutical companies should anticipate more calls for transparency in clinical studies. At the same time, organizations should continue to be mindful of best practices when it comes to anonymizing and securing data. Future compliance may require organizations to anonymize patient-level data at an earlier stage in the clinical trial process. In anticipation of those changes, companies should proactively develop policies and procedures for implementing long-term solutions to anonymization.
Applications which must be submitted through this procedure, and not national procedures, are: certain biotechnology products; advanced therapy medicinal products; new active substances with certain therapeutic substances (such as cancer); and orphan medicines.
These techniques are consistent with the Article 29 Working Party’s Opinion 05/2014 (WP216) on Anonymisation Techniques.
Publication
Le 19 avril dernier, la Cour suprême du Canada a rendu une décision fort attendue en matière de syndicalisation des cadres.
Publication
Le budget 2024 propose d’élargir la portée de certains pouvoirs permettant à l’ARC de demander des renseignements aux contribuables tout en prévoyant de nouvelles conséquences pour les contribuables contrevenants.
Publication
L'impôt minimum de remplacement (IMR) est un impôt sur le revenu additionnel prévu dans la Loi de l’impôt sur le revenu (Canada) (la « Loi ») auquel sont assujettis les particuliers et certaines fiducies qui pourraient autrement avoir recours à certaines déductions et exemptions et à certains crédits pour réduire leur impôt sur le revenu fédéral canadien régulier.
Abonnez-vous et restez à l’affût des nouvelles juridiques, informations et événements les plus récents...
© Norton Rose Fulbright LLP 2023